Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567883 | 0.92 | DRD2 (0.54) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL21677886 | 0.87 | MAPT (0.51) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL6228523 | 0.83 | MAPT (0.65) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL2561735 | 0.83 | MAPT (0.54) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL745595 | 0.82 | HSPB1 (0.50) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL9570575 | 0.81 | DRD2 (0.65) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL12274410 | 0.80 | KCNH2 (0.60) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL6485811 | 0.80 | MAPT (0.51) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL5390369 | 0.80 | HRH3 (0.69) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL10554981 | 0.80 | HRH3 (0.69) | KCNH2DRD2DRD4DRD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423753-A | Heterobicyclic amides as CD38 inhibitors | 里邦医疗公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-2488493-B1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8329904-B2 | Azacyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2488493-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2011045292-A1 | SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | KCNH2 2927/4885DRD2 4328/4885DRD4 4119/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | KCNH2 2798/4885DRD2 3735/4885DRD4 3898/4885 |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | KCNH2 3813/4885DRD2 4577/4885DRD4 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.